オーストラリア - 英語 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

omni chemicals - benzalkonium chloride - algicide - swimming pool - algae

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - somatropin, quantity: 10 mg - injection, solution - excipient ingredients: phenol; poloxamer; sodium hydroxide; phosphoric acid; monobasic sodium phosphate dihydrate; dibasic sodium phosphate heptahydrate; water for injections; glycine - omnitrope is intended for the long term treatment of children (above three years of age) with, growth disturbance due to insufficient secretion of pituatary growth hormone, growth disturbance associated with gonadal dysgenesis (turner syndrome), growth disturbance associated with chronic renal insufficiency.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - somatropin, quantity: 3.3 mg/ml - injection - excipient ingredients: poloxamer; dibasic sodium phosphate heptahydrate; benzyl alcohol; sodium hydroxide; monobasic sodium phosphate; mannitol; water for injections; phosphoric acid - omnitrope is intended for long term treatment of children (above three years of age with growth disturbance due to insufficient secretion of pituitary growth hormone; growth disturbance associated with gonadal dysgenesis (turner's syndrome); & growth disturbance associated with chronic renal insufficiency.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - somatropin, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; phenol; phosphoric acid; water for injections; sodium chloride; monobasic sodium phosphate dihydrate; dibasic sodium phosphate heptahydrate; poloxamer - omnitrope is intended for the long term treatment of children (above three years of age) with:,- growth disturbance due to insufficient secretion of pituitary growth hormone,- growth disturbance associated with gonadal dysgenesis (turner syndrome),- growth disturbance associated with chronic renal insufficiency.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - somatropin, quantity: 10 mg - injection, solution - excipient ingredients: phenol; poloxamer; sodium hydroxide; phosphoric acid; monobasic sodium phosphate dihydrate; dibasic sodium phosphate heptahydrate; water for injections; glycine - omnitrope is intended for the long term treatment of children (above three years of age) with, growth disturbance due to insufficient secretion of pituatary growth hormone, growth disturbance associated with gonadal dysgenesis (turner syndrome), growth disturbance associated with chronic renal insufficiency.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - gadodiamide, quantity: 287 mg/ml - injection - excipient ingredients: caldiamide sodium hydrate; sodium hydroxide; water for injections; hydrochloric acid - omniscan is indicated for use in adults and children from 6 months of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity and whole body imaging. indications as at 25 june 2003: omniscan is indicated for: 1) use in adults and children, including infants and neonates less than 6 months of age for the enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity, and; 2) whole body imaging for adults and children over 6 months of age.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - gadodiamide, quantity: 287 mg/ml - injection - excipient ingredients: water for injections; caldiamide sodium hydrate; sodium hydroxide; hydrochloric acid - omniscan is indicated for use in adults and children from 6 months of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity and whole body imaging. indications as at 25 june 2003: omniscan is indicated for: 1) use in adults and children, including infants and neonates less than 6 months of age for the enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity, and; 2) whole body imaging for adults and children over 6 months of age.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - gadodiamide, quantity: 287 mg/ml - injection, solution - excipient ingredients: caldiamide sodium hydrate; hydrochloric acid; water for injections; sodium hydroxide - omniscan is indicated for use in adults and children from 6 months of age for enhancement of magnetic resonance imaging of intracranial and spinal lesions where there is an abnormal blood-brain barrier of abnormal vascularity. indications as at 10 december 1999: omniscan is indicated for use in adults and children from 6 months of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity and whole body imaging. indications as at 25 june 2003: omniscan is indicated for: 1) use in adults and children, including infants and neonates less than 6 months of age for the enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity, and; 2) whole body imaging for adults and children over 6 months of age.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - iohexol, quantity: 518 mg/ml (equivalent: iodine, qty 240 mg/ml) - injection, solution - excipient ingredients: trometamol; sodium calcium edetate; hydrochloric acid; water for injections - indications as at 12 november 2003: intravascular: omnipaque is indicated in adults for angiography, excretory urography and contrast enhancement in computerised tomography. in children, omnipaque is indicated for angiography and urography. oral/body cavities: omnipaque is indicated in adults for arthrography, endoscopic retrograde pancreatography (erp), endoscopic retrograde cholangiopancreatography (ercp), herniography, hysterosalpingography and in adults, children and premature babies for studies of the gastrointestinal tract.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - iohexol, quantity: 647 mg/ml (equivalent: iodine, qty 300 mg/l) - injection, solution - excipient ingredients: trometamol; sodium calcium edetate; hydrochloric acid; water for injections - indications as at 12 november 2003: intravascular: omnipaque is indicated in adults for angiography, excretory urography and contrast enhancement in computerised tomography. in children, omnipaque is indicated for angiography and urography. oral/body cavities: omnipaque is indicated in adults for arthrography, endoscopic retrograde pancreatography (erp), endoscopic retrograde cholangiopancreatography (ercp), herniography, hysterosalpingography and in adults, children and premature babies for studies of the gastrointestinal tract.